Prostate Specific Antigen News and Research

RSS

Affordable Care Act that mandates free preventative services goes into effect in September

Starting in September, President Obama's Affordable Care Act will go into effect. The act mandates free preventative services such as cholesterol or breast cancer screenings and tetanus shots. But the question is, will doctors and patients take advantage of these new preventative services? "Unfortunately, thanks to our American healthcare system, we have been programmed to focus on treatment and not prevention," said Dr. David Samadi, a urologic oncologist specializing in prostate cancer treatment and robotic surgery, who is also the Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

26 Aug 2010

Research finds increased diagnostic activity among men with family history of prostate cancer

The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute.

20 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010

Researchers recommends robotic prostatectomy over traditional open surgery method

While sharp debate continues among medical professionals as to whether a radical prostatectomy performed with the assistance of a robotic device is more beneficial than the traditional open surgery method, research just published by investigators at The Cancer Institute of New Jersey (CINJ) shows new evidence supporting the safety of the robotic procedure - including what is believed to be one of the lowest complication rates to date. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

Report shows most men with low PSA undergo aggressive therapy

Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

Study on treatment needs of prostate cancer patients with low level PSA

Controversy has long existed over the benefit of the prostate specific antigen (PSA) test used to screen for the presence of prostate cancer, and there has been little study to document the risk profile of men who have a PSA level at or below what is considered 'normal.' New research published in the latest edition of Archives of Internal Medicine (Vol. 170, No. 14) by a team of investigators at The Cancer Institute of New Jersey (CINJ), further explores this population. The findings show that most men with prostate cancer who tested below the normal PSA level and had low-risk disease nevertheless underwent aggressive treatment. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

27 Jul 2010

Prostate cancer: To screen or not to screen

Men with a family history of prostate cancer who are confused about whether to undergo controversial screening could soon have access to an online resource to have their questions answered.

20 Jul 2010

Men with higher baseline PSA value more likely to die from prostate cancer, say researchers

Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values, according to Duke University Medical Center researchers.

9 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Claros point-of-care system for PSA receives European CE Mark approval

Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced the CE Mark approval for its rapid quantitative point-of-care diagnostic platform, which can now be used for prostate specific antigen (PSA) testing throughout the European Union. The approved system consists of a small portable analyzer and credit card-sized disposable.

29 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010